CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Recruiting now

Conditions studied: GVHD,Acute

In brief

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Key facts

Study ID

NCT05718791

Run by

Henry Ford Health System

People needed

100

Starts

2023-05-10

Expected to finish

2027-12-30

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients >18 year old admitted for allo SCT PB for malignant disease.

Where it is running

• Henry Ford Health System — Detroit, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.